ARCHIVES

FDA Breakthrough Designation Granted to Pfizer’s Palbociclib

This article is from The Cancer Letter archive.

Vol. 36 No. 4 | April 26, 2013

Download PDF Visit The Full Archive

Related Articles

Cancer, AIDS Patient Advocates List Drug Development Concerns

May 12, 1989

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

December 5, 2014

Sen. Specter Vows to “Stay and Fight” For Health, Education, On Subcommittee.

February 11, 2005

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

July 29, 2011

ACS Issues Challenge To cut Death Rate From Cancer In Half

November 22, 1996

ONF Seeks Applications For Grants In Fatigue

March 31, 1995